Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07038733 · ClinicalTrials.gov registry record · NA
Investigation of Lymph Node Biology in Kidney Cancer
A NA study of Renal Cell Carcinoma (RCC), sponsored by Yale University.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07038733 is a NA study of Renal Cell Carcinoma (RCC) that is actively recruiting participants, run by Yale University. The registered enrollment target is 10 participants, below the 441-participant average among 11 other Renal Cell Carcinoma (RCC) trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07038733, a NA study of Renal Cell Carcinoma (RCC), is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to investigate the phenotype, anti-tumor effector functions, and TCR repertoire of T cells isolated from patient tumor draining lymph nodes (TDLNs) to understand T cell priming and trafficking patterns in Renal Cell Carcinoma (RCC). Data and biospecimen collected will be used for current and future research projects involving the study of kidney cancer biology and related medical conditions. We will use this valuable resource to ask clinically relevant translational questions that pertain to biomarker discovery/validation, identification of novel therapeutic targets, and to better understand the genetic and biological basis of the various kidney cancers.
Conditions Studied
Interventions
- PROCEDURE Peripheral Blood Sample for Immune Analysis
- PROCEDURE Tumor Sample for Analysis
- PROCEDURE Adjacent non-malignant kidney for analysis
- PROCEDURE Draining lymph node(s) for analysis
- PROCEDURE Regional non-draining lymph node(s) for analysis
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-01-30 |
| Est. Completion | 2027-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07038733
The ClinicalTrials.gov registry entry for NCT07038733 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 441-participant average among 11 other Renal Cell Carcinoma (RCC) trials with a reported enrollment target (98% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma (RCC) appearing as the primary indexed condition, and to 5 interventions - of which Peripheral Blood Sample for Immune Analysis is the first listed.
NCT07038733 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT07038733 about?
NCT07038733 is a clinical study titled "Investigation of Lymph Node Biology in Kidney Cancer". The purpose of this pilot study is to investigate the phenotype, anti-tumor effector functions, and TCR repertoire of T cells isolated from patient tumor draining lymph nodes (TDLNs) to understand T cell priming and trafficking patterns in Renal Cell Carcinoma (RCC). Data and biospecimen collected w...
What is the current status of trial NCT07038733?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2026-01-30. Estimated completion is 2027-12.
What conditions does trial NCT07038733 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma (RCC).
What interventions are being tested in trial NCT07038733?
The interventions under investigation include: Peripheral Blood Sample for Immune Analysis (PROCEDURE), Tumor Sample for Analysis (PROCEDURE), Adjacent non-malignant kidney for analysis (PROCEDURE), Draining lymph node(s) for analysis (PROCEDURE), Regional non-draining lymph node(s) for analysis (PROCEDURE).
Who is sponsoring clinical trial NCT07038733?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07038733 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma (RCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"
RECRUITING · NA
-
ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses
RECRUITING · NA
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
-
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
RECRUITING · Phase 3
-
A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.